(Q43410555)

23 November 2017

Magnetic resonance imaging for monitoring the effects of thalidomide on experimental human breast cancers (English)

1 reference

23 November 2017

0 references

2

Barbara Sennino

1 reference

23 November 2017

Clemens C Cyran

1

1 reference

23 November 2017

Bundit Chaopathomkul

3

1 reference

23 November 2017

Yanjun Fu

4

1 reference

23 November 2017

Victor S Rogut

5

1 reference

23 November 2017

David M Shames

6

1 reference

23 November 2017

Michael F Wendland

7

1 reference

23 November 2017

Donald M McDonald

8

1 reference

23 November 2017

Robert C Brasch

9

1 reference

23 November 2017

language of work or name

English

0 references

publication date

30 July 2008

1 reference

23 November 2017

1 reference

23 November 2017

19

1 reference

23 November 2017

1

1 reference

23 November 2017

121-131

1 reference

describes a project that uses

23 November 2017

ImageJ

1 reference

11 June 2022

https://www.ebi.ac.uk/europepmc/webservices/rest/PMC5685658/fullTextXML

inferred from PubMed Central ID database lookup

cites work

MR monitoring of cyclooxygenase-2 inhibition of angiogenesis in a human breast cancer model in rats.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5685658

Effect of thalidomide on colorectal cancer liver metastases in CBA mice.

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5685658

Continuous low-dose (metronomic) chemotherapy on rat prostate tumors evaluated using MRI in vivo and comparison with histology

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5685658

Tumor microvascular changes in antiangiogenic treatment: assessment by magnetic resonance contrast media of different molecular weights.

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5685658

Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5685658

MRI monitoring of tumor response following angiogenesis inhibition in an experimental human breast cancer model

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5685658

The treatment of advanced renal cell cancer with high-dose oral thalidomide

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5685658

Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5685658

A randomized phase II trial of thalidomide, an angiogenesis inhibitor, in patients with androgen-independent prostate cancer.

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5685658

Openings between defective endothelial cells explain tumor vessel leakiness

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5685658

Continuous low dose Thalidomide: a phase II study in advanced melanoma, renal cell, ovarian and breast cancer

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5685658

Phase II trial of the antiangiogenic agent thalidomide in patients with recurrent high-grade gliomas

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5685658

Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5685658

Thalidomide as an anti-TNF-alpha inhibitor: implications for clinical use.

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5685658

Quantification of liver blood volume: comparison of ultra short TI inversion recovery echo planar imaging (ULSTIR-EPI), with dynamic 3D-gradient recalled echo imaging.

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5685658

Thalidomide exerts its inhibitory action on tumor necrosis factor alpha by enhancing mRNA degradation

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5685658

Thalidomide is an inhibitor of angiogenesis

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5685658

Thalidomide selectively inhibits tumor necrosis factor alpha production by stimulated human monocytes

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5685658

Multifocal epithelioid hemangioendothelioma: case report of a clinical chamaeleon.

25 May 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5685658

The choice of region of interest measures in contrast-enhanced magnetic resonance image characterization of experimental breast tumors.

15 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5685658

Thalidomide treatment reduces apoptosis levels in bone marrow cells from patients with myelodysplastic syndromes.

15 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5685658

Thalidomide-induced antiangiogenic action is mediated by ceramide through depletion of VEGF receptors, and is antagonized by sphingosine-1-phosphate

15 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5685658

Thalidomide in the treatment of patients with hepatocellular carcinoma: a phase II trial

15 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5685658

Thalidomide down-regulates the expression of VEGF and bFGF in cisplatin-resistant human lung carcinoma cells.

15 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5685658

Antiangiogenic activity of N-substituted and tetrafluorinated thalidomide analogues

15 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5685658

Comparison of MR contrast-enhancing properties of albumin-(biotin)10-(gadopentetate)25, a macromolecular MR blood pool contrast agent, and its microscopic distribution

15 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5685658

Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients

15 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5685658

Inhibition of NF-kappa B activity by thalidomide through suppression of IkappaB kinase activity

15 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5685658

Quantification of the extraction fraction for gadopentetate across breast cancer capillaries

15 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5685658

Magnetic resonance imaging detects suppression of tumor vascular permeability after administration of antibody to vascular endothelial growth factor

15 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5685658

Correlation of dynamic contrast-enhanced magnetic resonance imaging with histologic tumor grade: comparison of macromolecular and small-molecular contrast media

15 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5685658

Quantification of tissue gadolinium concentration using magnetic resonance imaging: comparison of ultrashort inversion time inversion recovery echoplanar and dynamic three-dimensional spoiled gradient-recalled approaches with in vitro measurements

15 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5685658

Activity of thalidomide in AIDS-related Kaposi's sarcoma

15 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5685658

Durable clinical response of refractory hepatocellular carcinoma to orally administered thalidomide

3 November 2018

1 reference

12 December 2020

Thalidomide in the treatment of relapsed multiple myeloma

1 reference

12 December 2020

A resource facility for kinetic analysis: modeling using the SAAM computer programs

1 reference

12 December 2020

The saga of thalidomide. Neuropathy to embryopathy, with case reports of congenital anomalies

1 reference

12 December 2020

10.1007/S00330-008-1111-X

Identifiers

DOI

1 reference

23 November 2017

1 reference

23 November 2017

PubMed publication ID

18665367

1 reference